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Abstract
The high incidence of acute and chronic kidney injury due to various environmental factors
such as heavy metals or chemicals has been a major problem in developing countries.
However, the diagnosis of kidney injury in these areas can be more challenging due to the
lack of highly sensitive and specific techniques that can be applied in point-of-care settings.
To address this, we have developed a technique called ‘micro-urine nanoparticle detection
(μUNPD)’, that allows the detection of trace amounts of molecular markers in urine. Specifi-
cally, this technique utilizes an automated on-chip assay followed by detection with a hand-
held device for the read-out. Using the μUNPD technology, the kidney injury markers KIM-1
and Cystatin C were detected down to concentrations of 0.1 ng/ml and 20 ng/ml respec-
tively, which meets the cut-off range required to identify patients with acute or chronic kid-
ney injury. Thus, we show that the μUNPD technology enables point of care and non-
invasive detection of kidney injury, and has potential for applications in diagnosing kidney
injury with high sensitivity in resource-limited settings.
Introduction
The occurrence of acute kidney injury (AKI) and chronic kidney disease (CKD) has been a
major problem in poor, rural, agricultural communities in parts of Central America, Sri Lanka,
and India [1]. The exact etiology of CKD in these communities still remains a mystery. How-
ever, it has been suggested that exposure to various environmental factors such as heavy metals,
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pesticides, other chemicals or plant products are associated with high prevalence of CKD, even-
tually requiring dialysis or kidney transplantation [2–4]. The traditional biomarkers of CKD
and AKI are blood urea nitrogen (BUN), serum creatinine (SCr), and urinary albumin, markers
which have been in place in clinical practice for decades but have limitations with respect to
sensitivity, specificity, and timeliness of diagnosis [5,6]. Serum biomarker measurements also
require drawing blood from patients, with repeated sampling when the diagnosis results are
positive. Thus, the procedure can be challenging, costly and impractical in rural areas. There-
fore, low-cost, non-invasive techniques using urine which allow point-of-care analyses are
highly desirable.
The detection of urinary rather than serum markers has provided a major advantage in
monitoring AKI due to the non-invasiveness and simplicity of the sampling procedure [7–9].
Soluble proteins or other biomolecules, such as kidney injury molecule-1 (KIM-1), Cystatin C,
and neutrophil gelatinase-associated lipocalin (NGAL) have been reported to be present at
high levels in the urine of patients with acute or chronic kidney injury [10–13]. However, most
of these studies have utilized complex instruments (e.g. Luminex), which have high sensitivity
but are impractical for rural testing. A test-strip method based on colorimetric detection was
developed, and would have been more useful for diagnoses in point-of-care or home settings,
but lacked a quantitative read-out system and the required sensitivity [14].
Recently, magnetic nanoparticle-based diagnostics have shown broad utility for the detec-
tion of different human diseases such as cancer [15,16] and infectious diseases [17,18]. Diag-
nostic targets, in the form of cells or extracted molecular components, are labeled with
magnetic nanoparticles which are then detected by a miniaturized nuclear magnetic resonance
device (μNMR). Not only the device is portable allowing diagnosis in resource-limited settings,
but also the detection based on magnetic resonance is highly sensitive due to the low back-
ground signals. In addition, the utilization of nanoparticles increases the molecular density of
ligands, enabling rapid and efficient labeling of disease targets [19,20]. The method can be inte-
grated into an on-chip, automated system, and exhibited extremely high sensitivity allowing
the detection of single cell targets from complex biological fluids such as whole blood [21].
Here, we describe the development of a semi-automated, nanoparticle labeling procedure
designed to detect soluble protein markers KIM-1 and Cystatin C in urine, which we have
termed micro-urine nanoparticle detection (μUNPD). KIM-1 is a type I cell membrane glyco-
protein which upon acute kidney injury, is highly expressed in the apical membrane of proxi-
mal tubules and releases its ectodomain into the urine [11]. Cystatin C is an inhibitor of
cysteine proteases which is expressed in all human nucleated cells, and has been shown to be
upregulated in various pathological conditions including states of chronic and acute kidney
injury [13]. We assessed the feasibility of the technology by measuring limit of detection for
both markers, as well as testing clinical samples from 42 different individuals that were either
patients with kidney disease or healthy volunteers. We found that our miniaturized magnetic
detection method, μUNPD, provided quantitative read-out signals with high sensitivity.
Methods
Microfluidic device fabrication and assembly
The microfluidic devices were fabricated by stacking three layers of polydimethylsiloxane
(PDMS; Dow Corning) on a glass slide. The cast molds for the bottom and top layers were pre-
pared by patterning a 50 μm thick single layer of epoxy-based SU8-3050 photoresist (Micro-
chem). A filter PDMS block was separately prepared by sandwiching a membrane filter
(400 nm pore diameter: Nuclepore, Whatman) with two PDMS slabs. Prior to assembly of the
block, the membrane filter was cut into a circular shape (5 mm in a diameter), 1mm thick
Point-of-Care Diagnosis of Kidney Injury
PLOS ONE | DOI:10.1371/journal.pone.0133417 July 17, 2015 2 / 11
T2Biosystems, a biotechnology companies
developing magnetic diagnostics for medical
applications. T2Biosystems did not support the
research herein, and the company has no rights to
any technology or intellectual property developed as
part of this research.
PDMS slabs were diced into 7×7 mm2 and a hole (2.5 mm in a diameter) was punched in the
center for vertical connection between bottom and upper channels through the filter. Then, the
three parts were aligned and bonded using uncured PDMS as a glue. The channel patterns
were replicated into the bottom layer (thickness, 1 mm) by pouring and curing PDMS, while
additional fluidic channels were contained within the separate top PDMS layer (thickness 1
mm). In the bottom PDMS layer a hole (2 mm in a diameter) were generated to connect the
bottom fluidic channel to filter and upper channel. Then, the PDMS filter block was aligned
and glued on top of the bottom layer. Uncured PDMS polymer was then poured over the
assembly, forming the intermediate layer (final thickness, 2 mm). After the polymer had cured,
the top PDMS layer was then irreversibly bonded to the intermediate layer via oxygen plasma
treatment. Inlet and outlet reservoirs were punched out, and the assembled device was finally
bonded irreversibly to a glass slide.
Preparation of assay reagents
For preparation of the capture beads, 1 mg of carboxylated polystyrene beads (diameter, 3 μm;
Polysciences) were reacted with 1.92 mg of 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide
hydrochloride (EDC, Sigma-Aldrich) and 1.15 mg ofN-hydroxysulfosuccinimide (sulfo-NHS,
Thermo Scientific) in phosphate buffered saline (PBS, pH 7.4) for 4 hr at room temperature.
After washing the unreacted chemicals using centrifugal filters (0.45 μm,Millipore), the beads
were then added with 100 μg of goat polyclonal antibody to human KIM-1 (R&D Systems) or
goat polyclonal antibody to human Cystatin C (R&D Systems), and reacted for 12 hr in PBS with
10 mM sodium bicarbonate at room temperature. The beads were finally washed with centrifugal
filters to remove the unreacted antibody. For preparing the detection antibody conjugates (Ab-
TCO), 100 μg of polyclonal antibody to KIM-1 or Cystatin C in PBS including 10 mM sodium
bicarbonate were added with 94 μg of trans-cyclooctene N-hydroxy-succinimidyl ester
(TCO-NHS) in dimethylformamide (molar ratio 1:500) and reacted for 4 hr in room tempera-
ture. The antibodies were purified using Zeba columns (MWCO 7,000, Thermo Scientific). The
magnetic nanoparticle conjugates (MNP-Tz) were prepared by adding 0.5 mg of amine-modified
iron oxide nanoparticles (diameter, 5 nm or 30 nm; Ocean Nanotech) in PBS including 10 mM
sodium bicarbonate with 472 μg of 2,5-dioxopyrrolidin-1-yl 5-(4-(1,2,4,5-tetrazin-3-yl)benzyla-
mino)-5-oxopentanoate (tetrazine-NHS) in dimethylsulfoxide and reacted at room temperature
for 4 hr. The nanoparticles were purified using centrifugal filters (Amicon Ultra, MWCO
100,000; Millipore).
Clinical samples
Ethical approval for the clinical studies were obtained from the Harvard School of Public
Health Institutional Review Board (IRB), Brigham and Women’s Hospital (BWH) Office of
Human Research Administration, and the Faculty of Medical Sciences, University of Sri Jaya-
wardenepura, Sri Lanka with permission from The Ministry of Health, Colombo, Sri Lanka. All
subjects were approached after obtaining verbal consent from the physician of record to
describe the study. Subjects were informed that participation is entirely voluntary and will no
way affect their medical care. Written informed consent was obtained from all participants.
The respective institutional review board approved the written consent prior to the start of the
study.
Sri Lankan cohort—Chronic kidney disease (CKD). A subset of samples collected for
urinay biomarker and toxic metal evaluation in CKD patients and controls were used for this
study. Urine samples (n = 18) were collected from individuals with CKD patients attending a
renal clinic at Medawachchiya hospital in the North Central Province of Sri Lanka. Patients
Point-of-Care Diagnosis of Kidney Injury
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with CKD had serum creatinine levels greater than 2 mg/dL, with an estimated glomerular fil-
tration rate (eGFR) lower than 60 ml/min/1.73m2. A group of 18 healthy individuals from the
Western Province in Sri Lanka who are not engaged in farming and living in the endemic area
likely to be exposed to same environmental risk factors were invited to participate as controls
as healthy individuals.
BWH cohort—Acute kidney injury (AKI). Urine samples were collected from ICU
patients (n = 3) at Brigham and Women’s Hospital (BWH) with approval of the IRB of BWH.
AKI was defined as an increase of serum creatinine of at least 100% over baseline values. Urine
samples were also collected from 3 healthy volunteers as controls.
Magnetic nanoparticle assay (μUNPD)
For performing the magnetic immuno-sandwich assay in high-throughput, the capture beads
for either KIM-1 or Cystatin C were added with the target solution in micro-well filter plates
(Multiscreen, Millipore) and incubated at room temperature for 45 min. Unbound target was
removed by washing with PBS including 0.05% Tween (PBS-T) and suction using a vacuum
manifold (Millipore). The capture beads were then added with the detection antibody conju-
gates (Ab-TCO) for KIM-1 or Cystatin C in PBS including 1 mg/ml bovine serum albumin and
2% fetal bovine serum (PBS++), incubated at room temperature for 45 min, and washed with
PBS-T. Finally, the magnetic nanoparticles (MNP-Tz) were added at 50 μg/ml for the 30 nm
(KIM-1) or 100 μg/ml for 5 nm (Cystatin C) particles in PBS++ and incubated for 20 min at
room temperature, followed by washing with PBS-T. For the automated, on-chip procedure,
the capture beads were added in the inlet of the micro-chip (Fig 1). The target solution was also
Fig 1. Schematic illustration of the μUNPD assay for urinary marker detection. Capture antibody conjugated-microbeads, detection antibodies (TCO
conjugated), and magnetic nanoparticles (Tz conjugated) are sequentially added to the urine specimen in a microchip, for subsequent read-out
measurements using the μNMR device.
doi:10.1371/journal.pone.0133417.g001
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added into the inlet, and the beads were allowed to mix with the target by flowing through the
micro-channels by applying negative pressure. Washing solution (PBS-T) was added to the
‘outlet’ and ‘inlet’, alternatively. The detection antibody conjugates (Ab-TCO) and magnetic
nanoparticles (MNP-Tz) were also sequentially applied to the inlet of the micro-chip, with
washing steps performed in between as described above. As the target solution, either the puri-
fied recombinant protein of KIM-1 or Cystatin C in buffer solution, or the clinical samples
(undiluted for KIM-1, and 5x diluted in PBS++ for Cystatin C) were added to the capture
beads.
After the assay, samples were reconstituted in 10 ul PBS and applied into polyimide tubings
for T2 relaxation measurements using a miniaturized nuclear magnetic resonance device [22].
Transverse relaxation times were measured using Carr–Purcell–Meiboom–Gill pulse sequences
with the following parameters: echo time, 3 ms; repetition time, 4 s; number of 180° pulses per
scan, 900; number of scans, 7. All measurements were done in triplicate, and data are expressed
as mean ± standard deviation (SD). Limit of detection (LOD) values were determined by calcu-
lating 3×(SD of background signal).
Luminex assay
Luminex xMAP technology was used to measure urinary Cystatin C with the Human Kidney
Toxicity Multiplex Assay fromMillipore according to manufacturer instructions, and urinary
kidney injury molecule-1 (KIM-1) was measured using a previously established Luminex-
based assay [7,12]. Urinary creatinine concentration was measured using a kit from Cayman
Chemicals according to manufacturer instructions, and used to normalize protein biomarker
measurements to account for urinary volume differences.
Results
The μUNPD technology is currently a semi-automated, microchip-based nanoparticle detec-
tion method to measure trace amounts of biomarker proteins in urine. Fig 1 shows the overall
scheme of the μUNPD assay. First, microbeads coated with capture antibodies are incubated
with the urine sample, which contains the target protein. The unbound molecular components
are washed away and the detection antibody is added. After another washing step, the magnetic
nanoparticles (MNPs) are added for labeling, followed by the final washing step, and the
labeled beads are applied to the μNMR for T2 relaxation measurements. A bioorthogonal reac-
tion using trans-cyclooctene and tetrazine was introduced for chemically linking the detection
antibodies with the MNPs. All assay components were added to the inlet of the microfluidic
chip. On-chip channels allowed effective mixing, while a filter membrane acted as a barrier to
trap the beads while the solutions would flow through. The entire procedure was simple and
straightforward, taking only two hours to complete.
Validation of assay
The feasibility of the μUNPD assay was first validated with recombinant proteins of the urinary
markers spiked into urine or buffer solutions. Fig 2A shows the detection ranges of each
marker, with optimum sizes of the magnetic nanoparticles used for labeling. For KIM-1, a
robust concentration dependent response was observed with 30 nm magnetic nanoparticles
which had higher relaxivity values than 5 nm nanoparticles (Fig 2B). Larger nanoparticles with
a size of up to 200 nm showed much higher background signals, resulting in lower detection
sensitivity than the 30 nm nanoparticles. Detection sensitivity of the μUNPDmethod was
assessed by spiking in different amounts of recombinant protein into the buffer solution prior
to performing the assay. In contradistinction, Cystatin C can be present at much higher
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concentrations and therefore smaller nanoparticles can be used. Fig 2C and 2D shows that the
lower detection limits of KIM-1 and Cystatin C were 100 pg/ml and 20 ng/ml, respectively.
The proteins were also spiked into urine from a healthy individual, which showed similar sig-
nals compared to detection in buffer solution (Fig 2E and 2F). These detection limits are suffi-
cient to detect kidney injury.
Clinical testing
We next evaluated the clinical utility of the μUNPD assay using urine specimens from a mixed
cohort of 42 patients. The majority of this cohort was comprised of a group of Sri Lankan farm-
ers that had been diagnosed with chronic kidney disease (CKD; n = 18) or their age-matched
controls working in the same area that had no such diagnosis (n = 18). In addition, we included
samples from a group of ICU patients at BWH that had been diagnosed with acute kidney
Fig 2. Assay validation. A, Assay set-up for urinary marker detection. B, μNMR signals using MNPs with different sizes. * = p < 0.02, ** = p < 0.001,
ns = not significant. Detection sensitivity measurements using serial dilutions of recombinant KIM-1(C) and Cystatin C (D) in buffer solution. Inset in C shows
data points in low ranges of KIM-1. ΔR2 = R2 (sandwich)—R2 (bead only). E,F, Detection of KIM-1 (E) and Cystatin C (F) in 100% and 20% urine,
respectively. The urine used was from a healthy patient (no. 20) with ranges of KIM-1 and Cystatin C that were not detectable. Note that all the clinical
samples (in Fig 3) were analyzed based on the same dilution factors.
doi:10.1371/journal.pone.0133417.g002
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injury (AKI; n = 3) so that we could observe the higher limits of KIM-1 detection, as well as
control samples from healthy volunteers (n = 3) (Table 1). Fig 3A and 3B show the detected
levels of KIM-1 and Cystatin C in each sample, respectively. Protein concentrations were calcu-
lated based on calibrations from measuring spiked recombinant proteins (S1 Fig). All 21 con-
trols showed low levels of both KIM-1 and Cystatin C. All three patients in the AKI cohort
showed extremely high levels of KIM-1, while also showing a significant levels of Cystatin C.
KIM-1 was not found to be significantly elevated in any of the 18 patients from the CKD
Table 1. Human subjects.
Cohort Age, years SCr, mg/dL eGFR, ml/min/1.73m2
Sri Lankan cohort CKD, n = 18 56.8 (7.1)a 4.1 (2.2) 20.6 (9.6)
Healthy, n = 18 57.3 (8.6) 1.0 (0.1) 82.4 (15.0)
BWH cohort AKI, n = 3 48.0 (33.0) 2.6 (1.7) N/A
Healthy, n = 3 24.0 (3.5) N/A N/A
aData presented as mean (SD).
doi:10.1371/journal.pone.0133417.t001
Fig 3. Measurement of KIM-1 and Cystatin C in clinical samples using the μUNPD technology. Urine
samples were obtained from 21 patients with kidney injury (AKI, acute kidney injury, n = 3; CKD, chronic
kidney disease, n = 18) as well as 21 healthy individuals as controls. (A) KIM-1 levels were measured and
expressed based on the calibration from S1A Fig, without any dilution (100% urine). (B) Cystatin C levels
were measured and expressed based on calibration from S1B Fig, after 5X dilution in PBS (20% urine). * =
p < 0.002, ** = p < 0.0001.
doi:10.1371/journal.pone.0133417.g003
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cohort, whereas Cystatin C was elevated in 16 of these patients. Combined tests of KIM-1 and
Cystatin C had a specificity of 89% for all kidney injuries. These results were in agreement with
the measurements of KIM-1 and Cystatin C using a Luminex-based assay and confirm that
KIM-1 is a useful biomarker for AKI, while Cystatin C is associated with both AKI and CKD.
A direct comparison of measurements taken with the μUNPDmethod and luminex-based
assay showed good correlation for both biomarkers (Fig 4A and 4B; R2 = 0.8641 for KIM-1,
R2 = 0.9936 for Cystatin C).
Discussion
We show proof-of-principle that the magnetic μUNPD technology can be used to measure kid-
ney injury biomarkers KIM-1 and Cystatin C in urine samples using a handheld device. The
technology enables the detection of extremely low amounts of biomarkers present in the urine.
The intensity of read-out signals, which are T2 relaxation values, can be controlled by changing
the size of labeling material which vary in r2 relaxivity values. Larger particles have a higher
core-to-shell volume ratio resulting in higher relaxivity. The larger volume and perhaps surface
impurities leads to higher nonspecific binding. Using the biomarkers KIM-1 and Cystatin C,
the μUNPD method allowed the diagnoses and discrimination of both AKI and CKD in
patients via a non-invasive procedure. The results from the clinical studies correlate well with
the previous reports that KIM-1 is indicative of AKI, while Cystatin C can be a generic marker
for both acute and chronic injury [3].
A dipstick method for KIM-1 detection has previously been reported but showed a detection
limit of 0.8 ng/ml [14]. The μUNPD method, on the other hand, was able to quantitatively
detect KIM-1 with a lower detection limit of 0.1 ng/ml. High sensitivity is a key feature of mag-
netic detection, since T2 relaxation measurements based on magnetic nanoparticles show
highly intense signals with very low background and nonspecific signals, compared to existing
methods based on optical detection such as fluorescence measurements. Sensitivity is critical,
since KIM-1 is commonly present in urine at concentrations down to 0.1 ng/ml. We found the
detection sensitivity of our handheld point-of-care device to be comparable to the Luminex-
based assay [7], and thus clearly has financial and practical advantages for regions with limited
resources (equipment costs ~ $120,000 for Luminex technology vs ~ $1,000 for μUNPD
technology).
Fig 4. Correlation between μUNPD& luminexmethod.Detection of KIM-1 (A) and Cystatin C (B). Levels of biomarker proteins for μUNPD and luminex
were obtained from standard calibration curves from each method, individually.
doi:10.1371/journal.pone.0133417.g004
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Magnetic detection of disease targets based on nanoparticle labeling has been reported in
several studies previously [15,17,18]. However, this study is the first to 1) detect soluble mark-
ers, 2) directly from a patient specimen without any purification or processing steps, and 3)
through a non-invasive sampling procedure. The further identification of soluble urinary bio-
markers in other diseases such as cancer and infections would greatly broaden the applicability
of the μUNPD technology.
The utilization of bioorthogonal linkers also contributes to the high read-out signals and
rapidness of the procedure. The reaction between trans-cyclooctene and tetrazine is an ultra-
fast reaction with a second-order rate constant of 6,000 ± 200 M-1s-1 [23]. The small size of the
linkers also endows high molecular density of the linker on the magnetic material and ligand,
allowing their efficient and rapid binding to the target.
Finally, the automation of the assay in a micro-chip format reduces the need for training to
perform the assay, increasing the applicability of this approach as a point-of-care diagnostic.
We have shown here that KIM-1 and Cystatin C can be accurately and sensitively detected in
urine samples with our technique, and we envision that assays for other urinary markers, such
as NGAL, Clusterin and albumin, could also be easily adapted to our method. An extended
panel of markers would create a more informed platform, to further contribute in decision-
making and personalized treatment options. Although the measurements were obtained sepa-
rately for each marker in the current study, strategies to multiplex the assay are being explored.
Multiplexing would greatly improve the throughput of the assay and perhaps further reduce
costs. In addition, urine-based diagnostics can be complicated by the fact that variable amounts
of urine are produced among individuals. Advanced methods to normalize biomarker levels
should be further developed to minimize these complexities.
Conclusions
The current study presents a semi-automated, point-of-care method that can detect biomark-
ers in urine samples. The method is based on capture and nanoparticle-labeling of target pro-
teins followed by detection using a hand-held magnetic detection device. The technology is
highly sensitive, comparable to the standard Luminex-based assay, with low background sig-
nals, and simple which would allow its easy application for clinical diagnosis. The utilization of
urinary biomarkers KIM-1 and Cystatin C also provides advantages in maximizing specificity
and endowing simplicity in the procedure.
The occurrence of acute or chronic kidney injury due to various environmental factors has
been a major problem in poor, rural communities in developing countries. Most of these loca-
tions are limited in resources and poorly accessible to hospital facilities, requiring a simple,
point-of-care technology for diagnosing kidney injury. The μUNPD technology, which is much
more sensitive than the previously developed dipstick method, will greatly benefit these commu-
nities in identifying patients’ conditions and allowing subsequent treatment procedures.
Supporting Information
S1 Fig. Conversion of NMR signals. Calibration plot to convert NMR signals into KIM-1 (A)
and Cystatin C (B) levels in the clinical samples.
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